Granules India Reports Strong Q2 Growth, Secures FDA Approval for New Facility

Granules India Limited , a prominent pharmaceutical company, has reported robust financial results for the second quarter, marking significant progress in its growth trajectory and regulatory compliance efforts.

Financial Highlights

Granules India achieved impressive financial results in Q2:

Metric	Q2	Q2 Previous Year	YoY Growth
Revenue	12,970.00	9,666.00	34.00%
Gross Margin	65.70%	62.02%	368 bps
EBITDA	2,782.00	2,033.00	36.80%
EBITDA Margin	21.50%	21.08%	42 bps

The company's strong performance was primarily driven by growth in its formulations business in North America and Europe. The gross margin improvement of 368 basis points year-on-year was attributed to enhanced operational efficiency and a favorable product mix.

Regulatory Milestones

Granules India has made significant strides in regulatory compliance and facility approvals:

Gagillapur Facility: The company has secured a meeting with the U.S. FDA to discuss remediation efforts at its Gagillapur facility. Granules continues to submit monthly progress reports and has received no concerns from the FDA regarding the adequacy or pace of its corrective actions.
Genome Valley Facility: The company's greenfield GLS facility at Genome Valley, Hyderabad, received U.S. FDA approval for a product following a Pre-Approval Inspection (PAI). This marks the first FDA approval for the GLS site, strengthening Granules' finished dosage capabilities and enabling multi-site manufacturing.
Other Facilities: The company's GPI site in Chantilly, Virginia, and API Unit 1 facility at Bonthapally have both received positive outcomes from recent FDA inspections.

Strategic Developments

Granules India is focusing on several strategic initiatives to drive future growth:

European Expansion: The company has incorporated a German subsidiary to support its growth plans in the European Union market.
Peptide CDMO Platform: Ascelis Peptides, built on Senn Chemical's Swiss legacy, is progressing through its integration and capability-building phase. The company expects this segment to turn profitable in the future.
Controlled Substances: Granules anticipates significant growth in its controlled substances business over the next 3 to 10 years, with products filed until 2035.

Outlook

Dr. Krishna Prasad Chigurupati, Chairman and Managing Director, expressed confidence in the company's future, stating, "We are entering the phase of reviving our growth with a stronger quality foundation, expanded capacity, and a more diversified portfolio."

The company expects near-term momentum to be driven by the ramp-up of prescription supplies from the Genome Valley facility, continued growth from U.S. manufacturing operations, and expected normalization of operations at Gagillapur post-remediation.

Granules India remains committed to its sustainability goals and disciplined execution, aiming to deliver sustained value to all stakeholders in the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.61%	+2.87%	-1.38%	+9.05%	+0.97%	+47.64%

Granules India Limited , a vertically integrated pharmaceutical company, has announced significant changes in its senior management team, effective November 2025. The company has appointed Vinodkumar Parur as the new Chief Human Resources Officer (CHRO), while the current CHRO, Atul Dhavle, is set to depart.

New CHRO Appointment

Vinodkumar Parur will assume the role of Chief Human Resources Officer at Granules India Limited, effective November 17, 2025. With this appointment, Parur will also be designated as Senior Management Personnel within the organization.

Parur brings over 24 years of extensive HR leadership experience across various sectors, including manufacturing, engineering, pharmaceuticals, and infrastructure. His impressive career includes senior roles at prominent companies such as RR Kabel Limited and Nilkamal Limited.

Professional Background

Vinodkumar Parur's expertise spans several critical areas of human resources management:

HR function setup for IPO preparation
Mergers and acquisitions
Implementation of HRMS systems
Leadership development
Employee engagement programs

Prior to joining Granules India, Parur held the position of Chief Human Resources Officer at both RR Kabel Limited and Nilkamal Limited. He has also served in senior HR leadership roles at A.T.E. Group and Schindler India.

Educational Qualifications

Parur holds a master's degree in management studies (Human Resources) from PIMSR, Mumbai University, and a bachelor's degree in commerce and economics from NMIMS, Mumbai University. His educational background is complemented by certifications in various HR assessment and training programs.

Current CHRO's Departure

Atul Dhavle, the current Chief Human Resources Officer of Granules India Limited, has tendered his resignation to explore other opportunities. Dhavle will cease to be Senior Management Personnel effective November 16, 2025. To ensure a smooth transition, he will serve a notice period, during which he will assist in handing over his responsibilities.

Company's Perspective

Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited, expressed confidence in the new appointment: "We are pleased to welcome Vinodkumar Parur to our senior management team. His extensive experience and expertise in human resources management across various industries will be invaluable as we continue to grow and develop our workforce."

The leadership changes come at a time when Granules India is focusing on operational excellence and long-term value creation. The company recently reported a 34% year-on-year growth in revenue from operations for Q2 FY26, reaching INR 12,970.00 million, with a 37% increase in EBITDA to INR 2,782.00 million.

These management changes are expected to support Granules India's ongoing efforts in talent management and organizational development as the company continues to strengthen its position in the pharmaceutical industry.